20% Upper Circuit: Pharma Stock Skyrockets After Reporting 1,135% YoY Net Profit Growth

Synopsis: NGL Fine Chem Limited reports 43.11% YoY revenue growth and a 1,135.43% YoY surge in net profit in Q3 FY26 results.

This Small-Cap Pharma Stock, engaged in manufacturing and exporting APIs, intermediates, and formulations for the veterinary and human health sectors worldwide, hit a 20 percent upper circuit after the company reported December quarterly results with a 1,135.43 percent YoY increase in net profit.

With a market capitalization of Rs. 1,351.91 crores, the shares of NGL Fine Chem Limited hit a 20 percent upper circuit of Rs. 2188.25 per share on Wednesday, up from its previous closing price of Rs. 1823.55 per share. 

Q3 FY26 Result

Coming into the quarterly results of NGL Fine Chem Limited, the company’s consolidated revenue from operations increased by 43.11 percent YOY, from Rs. 89.10 crore in Q3 FY25 to Rs. 127.51 crore in Q3 FY26, and grew by 6.03 percent QoQ from Rs. 120.26 crore in Q2 FY26.

In Q3 FY26, NGL Fine Chem Limited’s consolidated net profit increased by 1,135.43 percent YOY, reaching Rs. 15.69 crore compared to Rs. 1.27 crore during the same period last year. As compared to Q2 FY26, the net profit has increased by 63.10 percent, from Rs. 9.62 crore.

The basic earnings per share increased by 1,127.05 percent and stood at Rs. 25.40 as against Rs. 2.07 recorded in the same quarter in the previous year, FY2025. NGL Fine Chem Limited’s revenue and net profit have grown at a CAGR of 19.34 percent and 21.29 percent, respectively, over the last five years.

In terms of return ratios, the company’s ROCE and ROE stand at 9.44 percent and 7.75 percent, respectively. NGL Fine Chem Limited has an earnings per share (EPS) of Rs. 56.8, and its debt-to-equity ratio is 0.29x.

Global Presence

NGL Fine Chem Limited caters to global markets across more than 45 countries, maintaining strong relationships with over 400 clients through cost-effective production and stringent quality controls.  The company maintains facilities in Navi Mumbai and Tarapur, Maharashtra, which feature advanced reactors and R&D capabilities for custom synthesis and process innovation.

NGL Fine Chem Limited was incorporated in 1981 and is headquartered in Mumbai, India. The company is a prominent manufacturer and exporter of pharmaceuticals and intermediates tailored for the veterinary and human health sectors. 

The company specializes in producing high-quality active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms, primarily serving the animal healthcare industry with a focus on antiprotozoal and anthelmintic therapies.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 20% Upper Circuit: Pharma Stock Skyrockets After Reporting 1,135% YoY Net Profit Growth appeared first on Trade Brains.